Navigation Links
Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
Date:5/15/2013

with afatinib discontinued treatment compared with 39.8 percent of patients treated with chemotherapy.1  

LUX-Lung 6 (Patient-Reported Outcomes) Abstract: #8061
Poster: Saturday, June 1, 8:00-11:45 AM, poster board #35A

Patient-reported outcomes (PROs) were also evaluated as secondary endpoints of the LUX-Lung 6 trial and included analyses of health-related quality of life (QoL) and lung cancer-related symptoms compared with chemotherapy.[5]

The analysis of lung cancer-related symptoms – cough, dyspnea (shortness of breath) and pain – was conducted using the European Organization for Research and Treatment of Cancer (EORTC) QoL questionnaire for lung cancer (QLQ-LC13).5 Results showed:

  • A higher proportion of patients in the afatinib arm, compared with those in the chemotherapy arm, reported 10 point or more improvements in cough (76% versus 55%; p=0.0003), dyspnea (71% versus 48%; p<0.0001) and pain (64% versus 47%; p=0.003)5
  • Afatinib-treated patients experienced a significant delay in the worsening (time to deterioration) of cough (HR=0.45; p=0.0001), dyspnea (HR=0.54; p<0.0001) and pain (HR=0.70; p=0.03) compared to those treated with chemotherapy5

Health-related QoL was evaluated using the EORTC QLQ-C30 questionnaire, which evaluated global health status/QoL (overall well-being) in addition to physical, cognitive, role, social and emotional functioning.6 Based on these measures, afatinib-treated patients experienced improvements in their global health-related QoL (p<0.0001) and physical (p<0.0001), role (p=0.01) and social (p<0.001) functioning compared to chemotherapy.5

A significantly higher proportion of afatinib-treated patients had worsening of diarrhea, sore mouth and dysphagia; while fatigue, nausea and vomiting were significantly worse with gemcit
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015  IRIDEX Corporation (NASDAQ: IRIX ... and full year 2014 financial results after the market closes ... the release, the Company will host a conference call with ... Thursday, March 5, 2015 to discuss the ... Interested parties may access the live conference call via telephone ...
(Date:2/26/2015)... , Feb. 26, 2015  Mail-service and ... consumers, employers and government health plans $23.3 ... released by the Pharmaceutical Care Management Association (PCMA). ... drugs offers one of the easiest ways to ... Mark Merritt . "Policymakers should resist efforts ...
(Date:2/26/2015)... -- Every year many millions of donations are obtained ... year after year doctors and the medical profession continue ... to determine the status of heart health in all ... though that technology is over 100 years old, ... (while most patients do not know) that EKG,s, in ...
Breaking Medicine Technology:IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2National Heart Health Month In February 2
... as Marker of,Treatment Success -, SAN FRANCISCO, ... presented at the 59th Annual Meeting of,the American ... shows that,PEGASYS(R) (peginterferon alfa-2a) treatment regimens result in ... patients as,compared to regimens with another pegylated interferon.(1), ...
... Denmark, October 31 , - DoctorConsult in ... Improve Clinician Decision Making and Health Care Business,Performance, ... and more than a,century of experience as a ... provide interactive clinical reference and clinical decision,support (CDS) ...
Cached Medicine Technology:New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7Elsevier is Expanding eClinical Solutions in Europe 2Elsevier is Expanding eClinical Solutions in Europe 3
(Date:2/27/2015)... Wisconsin (PRWEB) February 27, 2015 Dr. ... plastic surgeons , is pleased to announce the expansion ... now open in Delafield. Quintessa has begun seeing patients ... the new Delafield location will offer a variety of ... including: Botox, filler injectables, micro laser peels, chemical peels, ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 On February 24 ... Real Liquid Botox ,” that details the development of ... is working its way through FDA trials. For those afraid ... cream is very attractive. Of course, if the drug ultimately ... at a physician’s office. (see: goo.gl/PQvQwk) , “As the article ...
(Date:2/27/2015)... Beach, FL (PRWEB) February 27, 2015 ... medical companies, devices and pharmaceuticals, Benedict Advertising & ... as its newest client. The company’s patented NITROUSEAL® ... a pain-free, no-stress method of sedation. , Sedation ... medical patient comfort to a new level, though ...
(Date:2/27/2015)... February 27, 2015 The winter season is ... and expansion. When mold grows, it can be harmful to ... to avoid the consequences of mold growth with the help ... is offering tips on the best ways to prevent mold ... which makes perfect conditions for mold to thrive. Mold must ...
(Date:2/27/2015)... 2015 Victorian Hotel recently celebrated Valentine’s ... who wanted to spend the auspicious day together. This ... a jump on Valentine’s Day with a sweet overnight ... of their luxurious rooms. , The hotel started ... for a mouthwatering 3 course meal at Café 335. ...
Breaking Medicine News(10 mins):Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:Is Topical Botox the Next Big Thing? 2Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:Enviro-Test Offers Tips for Winter Mold Prevention 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2
... of asthma-causing immune molecules Asthma and ... Soluble IgE molecules, produced by immune cells known as ... Therapeutic targeting of IgE in the blood can neutralize ... allergic asthma. However, this approach does not halt IgE ...
... was worse than physical abuse alone, study found , MONDAY, ... finds that older women who are exposed to physical and ... twist did show up in the results, study author Dr. ... more damaging than physical abuse alone. , Why? "The physical ...
... be wise, expert says, , MONDAY, May 10 (HealthDay ... its authors describe as a precise description of the ... heart-related fats. , It provides "the best evidence yet ... blood lipids profile," said Dr. Joan Sabate, who chairs ...
... ... Beard & Arsenault in Louisiana says the estimated 5,000 U.S. deaths each year from ... the most part preventable.” , ... Alexandria, LA (PRWEB) May 10, 2010 – Louisiana’s Department of Health and ...
... - The Massachusetts Eye and Ear Infirmary, Harvard Medical ... renewal from the National Institutes of Health, National Eye ... scientists to promote translational and clinical research into cures ... five-year K12 grant to Mass. Eye and Ear (representing ...
... ... ... E. Clyburn will give the commencement address at the 135th Commencement ceremony for Meharry Medical ... Lipscomb University in the Allen Arena. Doors open at 11:30 a.m., , , , ,Congressman Clyburn ...
Cached Medicine News:Health News:JCI online early table of contents: May 17, 2010 2Health News:JCI online early table of contents: May 17, 2010 3Health News:JCI online early table of contents: May 17, 2010 4Health News:JCI online early table of contents: May 17, 2010 5Health News:JCI online early table of contents: May 17, 2010 6Health News:JCI online early table of contents: May 17, 2010 7Health News:JCI online early table of contents: May 17, 2010 8Health News:Older, Abused Women Suffer Poor Mental Health 2Health News:Eating Nuts May Help Cholesterol Levels 2Health News:Eating Nuts May Help Cholesterol Levels 3Health News:Food Poisoning Suspected in 3 Deaths, 40 Illnesses at Central State Hospital in Pineville, LA 2Health News:Mass. Eye and Ear receives NEI grant renewal for 'growing' clinical/scientists 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 3
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Classic proven design with superior clinical results...
... Using high-performance materials contributes to ... addition to surgical procedures and technique, ... great bearing on your patients' outcomes, ... DePuy developed MARATHON Cross-Linked Polyethylene. MARATHON ...
Medicine Products: